ISN Journal summaries on belimumab in lupus nephritis and deceased donation in Tamil Nadu
Kidney International®
Lupus nephritis is complex and difficult to treat, and clinicians need better tools to understand which patients are most likely to benefit from specific therapies.
Using data from the Phase 3 BLISS-LN study, researchers assessed how belimumab affected immune biomarkers and whether these markers predicted kidney response.
They found that belimumab changed several biomarker patterns and identified signals linked to better kidney outcomes, supporting the future use of biomarkers to personalize lupus nephritis care.
Kidney International Reports®
Building a sustainable deceased donation ecosystem: The Tamil Nadu experience
Deceased donor transplantation requires coordination across clinical, administrative, legal, policy, media, and public domains.
This editorial examines Tamil Nadu’s deceased donation program, showing how transparent governance, standardized protocols, public recognition of donors, workforce training, and expanded retrieval capacity contributed to a stronger donation ecosystem.
The state recorded its highest-ever deceased donation activity in 2024, with 268 deceased donors and 1,500 organs and tissues retrieved and used, offering a model for strengthening ethically grounded, publicly trusted donation systems.
